Latest Breaking News On - Empagliflozin - Page 7 : comparemela.com

Boehringer Ingelheim: Empagliflozin shows consistent cardio-renal benefits in adults with heart failure with left ventricular ejection fraction over 40 percent regardless of chronic kidney disease status

In a new sub-analysis of the landmark EMPEROR-Preserved Phase III trial, empagliflozin reduced the combined relative risk of cardiovascular death and hospitalization for heart failure and slowed kidney

United statesStephan thalenFaiez zannadWaheed jamalStefanie molkenthinEli lillyJeff emmickGlobal business communicationsBoehringer ingelheimLilly allianceProgram clinical investigatorProduct developmentEuropean unionUniversity of lorraineAmerican society of nephrology kidney weekAmerican society

INVENTIVA: Inventiva announces the design of LEGEND, a Phase IIa combination trial with lanifibranor and SGLT2 inhibitor empagliflozin in patients with NASH and type 2 diabetes

The LEGEND trial is a proof-of-concept Phase IIa clinical trial to evaluate the safety and efficacy of lanifibranor in combination with the sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin

New yorkUnited statesPascaline clercAude lepreuxEli lillyPierre broquaPatricial bankBrunswick groupExchange commission onBoehringer ingelheimGlobal external affairsLong island cityEuronext parisChief scientist officerKey opinionBreakthrough therapy

Herzschwäche: Diabetes-Medikament hilft gegen spezielle Erkrankungsformen

Die chronische Herzschwäche (Herzinsuffizienz), an der allein in Deutschland rund vier Millionen Menschen leiden, ist bislang nur eingeschränkt behandelbar. Doch Forschende berichten nun, dass eine bestimmte Form der Erkrankung erstmals spezifisch behandelt werden kann – und zwar mit einem Diabetes-Medikament.

Charit virchowDoctor centerHeart weaknessHeart failureTreatment optionsItems certainMillion peopleYet research basedMedical centerShortness of breathActive ingredientTrade magazineKidney or brainQuality of lifeMedical clinicFocus cardiology charit virchow hospital

Trial shows benefit of Empagliflozin for heart failure with preserved ejection fraction patients

France: SGLT-2 inhibitor, Empagliflozin significantly reduced heart failure-related hospitalizations, regardless of patient diabetes status, reveal new EMPEROR-Preserved findings.Further it reduces.

Stefan ankerUniversity hospital berlinNew england journalProfessor stefan ankerHeart failurePreserved ejection fractionEuropean society of cardiologyHeart failure with preserved ejection fractionSglt2 inhibitorDiabetes medicationSglt 2 inhibitor

Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes

Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes
pharmiweb.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmiweb.com Daily Mail and Mail on Sunday newspapers.

United statesAvraham karasikWaheed jamalBoehringer ingelheimEli lillyAmerican diabetes associationHeart failure congressSackler school of medicineAmerican diabetes association scientific sessionsAviv universityEuropean society of cardiologyAnimal healthEast asiaEast asianScientific sessionsEuropean society